This message was sent to ##Email##
|
|
|
|
|
| |
| ACS CANCER PROGRAMS UPDATES |
ACS
The American College of Surgeons (ACS) has issued a call for abstracts to be presented at our 2019 Quality and Safety Conference, July 19-22, at the Walter E. Convention Center in Washington, D.C. The deadline for submitting abstracts is Feb. 1, 2019.
Individuals at participating sites are encouraged to submit a 250-word abstract for poster and/or podium presentation. The abstract should relate to surgical quality improvement initiatives including the development, implementation or validation of best practices within one or more of the following ACS Quality Programs:
- ACS National Surgical Quality Improvement Program (ACS NSQIP®)
- ACS Children’s Surgery Verification and ACS NSQIP Pediatric
- Cancer Programs, including the Commission on Cancer (CoC) and National Accreditation Program for Breast Centers (NAPBC)
- Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)
- Trauma Quality Programs, including Pediatrics, Verification, Trauma Quality Improvement Program (TQIP), and Performance Improvement and Patient Safety
Upcoming deadlines
Abstract submissions close Feb. 1, 2019
Acceptance notices sent May 1, 2019
READ MORE
|
Promoted by
|
|
|
|
 |
ACS
The Commission on Cancer (CoC) invites all practicing physicians at CoC-accredited programs to submit an application to join the CoC Surveyor Team. If you are passionate about the CoC and its Standards, we are looking for you! Consider becoming part of the CoC Surveyor team and share your commitment for providing patients with high-quality, patient-centered, multidisciplinary care.
In order to meet the ever-increasing number of programs interested in CoC accreditation, we need your support and expertise. Click here to access the application.
If you have questions please contact accreditation@facs.org.
ACS
At Clinical Congress 2018, the inaugural SurgeonsVoice Advocate of the Year award was presented to Alan G. Thorson, MD, FACS, a colon and rectal surgeon in Omaha, Nebraska, for his commitment to the American College of Surgeons (ACS) advocacy and political efforts, particularly through his involvement with the Commission on Cancer. Thorson will also be featured in the Bulletin of the American College of Surgeons.
READ MORE
 |
|
Our ihcDirect® method yields a revolutionary technology that opens a spectrum of new clinical applications including intraoperative surgery. Using the Novodiax PolyHRP technology, Intraoperative IHC tests can now be completed in just 10 minutes using fresh frozen tissues.
For more details, see our
 ihcDirect® product list.
|
|
ACS
CAnswer Forum: Clarification on the coding instructions for Brachytherapy and Radioembolization
Several questions related to the new radiation data items have been posted in the CAnswer Forum. For CoC-accredited programs, please follow STORE rules. To clarify the current coding instructions for brachytherapy and radioembolization:
1. For Phase I, II and III Dose per Fraction, NAACCR Data Items 1501, 1511 and 1521, use code 99998 when brachytherapy was administered to the patient (codes 07-12 for Phase I, Phase II or Phase III Treatment Modality, NAACCR Data Items 1506, 1516 or 1526).
2. For Phase I, II and III Total Dose, NAACCR Data Items 1507, 1517 and 1527, use code 999998 when brachytherapy was administered to the patient (codes 07-12 for Phase I, Phase II or Phase III Treatment Modality, NAACCR Data Items 1506, 1516 or 1526).
3. For Total Dose, NAACCR Data Item # 1533, use code 999998 when brachytherapy was administered (codes 07-12 recorded in Phase I, Phase II or Phase III Radiation Treatment Modality, NAACCR Data Items 1506, 1516 or 1526).
4. For Phase I, Phase II and Phase III Treatment Modality, NAACCR Data Items 1506, 1516 and 1526, use code 13 – Radioisotopes, NOS, for radioembolization procedures i.e. intravascular Yttrium-90, for cases diagnosed January 1, 2018 or later. For cases diagnosed prior to January 1, 2018, use code 07 – Brachytherapy, NOS.
For clarifications on the STORE data items, please continue to utilize the CAnswer Forum. For program-specific questions, please contact ncdb@facs.org.
READ MORE
AJCC
The AJCC Cancer Staging Manual, Eighth Edition is the first edition to have an electronic book (eBook) version. It is available for purchase now on Amazon and is the most current version of the manual (September 2018).
Since 1977, the American Joint Committee on Cancer (AJCC) has published eight editions of cancer staging manuals using contemporary, evidenced-based literature to build a common language of cancer for the care of cancer patients by clinicians and for the cancer surveillance community. The print version of the eighth edition was first published in October 2016 and went into effect for all cancer cases diagnosed on or after Jan. 1, 2018. The eighth edition presents evidence-based revisions for the staging of cancer for a number of organ sites. The chapters include the rationale and rules for staging; the definitions of tumor, lymph node involvement and metastasis; stage groupings; and histologic grade.
There have been updates since the first printing of the eighth edition, all of which are incorporated in this eBook version available through Amazon’s Kindle. The Kindle version can be used on any device (PC, MAC, iPhone, iPad, Android) with the free Kindle app. The electronic version allows for highlighting, adding notes and bookmarks and creating flashcards. The AJCC has a curated FAQ document to address common questions that can be accessed at cancerstaging.org. All other questions related to the eighth edition can be sent to ajcc@facs.org.
READ MORE
|
|
|
|
|
| |
ACS
April 7–9, 2019 – Rosemont (Chicago), Illinois
The 2019 Cancer Programs Cluster Workshops will be three individual one-day workshops on consecutive days, in one location, for your convenience. You may attend just one workshop or all three. Sign up here for further information as it becomes available.
|
Promoted by
|
|
|
|
 |
NCCRT
The 2017 national average for CRC screening in HRSA-funded health centers was released last month and is at 42 percent, which increased from 39.9 percent in 2015, meaning an additional 223,100 patients were screened in the last year alone and an additional 467,500 patients were screened in the last 2 years. That’s almost half a million people! Visit the HRSA website for an additional understanding of the rates. View our 80 percent by 2018 Hall of Fame to see the list of these centers that are meeting or exceeding our shared goal. (And if you or a partner you know of is exceeding 80 percent, you can submit them to the Hall of Fame!) Thanks to Laura Makaroff for sharing the data. Most importantly, congratulations to all our colleagues working in health centers, as well as to the many of you who work to support health centers on this continued improvement!
READ MORE
| HEALTH CARE NEWS AND UPDATES |
News-Medical
In a recent study, patients who were overdue for cancer screening were selected based on Ontario's guidelines: women aged 21 and older who had not received a Pap test in three years were overdue for cervical cancer screening, women who had not received a mammogram in the last two years and were older than 50 were overdue for breast cancer screening, and adults over the age of 50 who had not had a Fecal Occult Blood Test in the last two years or a colonoscopy in the last 10 years were overdue for colorectal cancer screening. Compared to the letter group, women who received a phone call were 25 percent more likely to receive screening, with 41 percent of women who were phoned receiving a screening, versus 33 percent of those who received a letter. Among men, 29 percent of those who received a phone call received screening, compared to 25 percent of those who received a letter.
READ MORE
 |
|
Clinical Cancer Coding is hard. HLA-Global’s Horizon uses advanced AI and Machine Learning to make the hard easy. Horizon has an average accuracy of 97%+ all of the time, works 24X7, costs 50% less than manual coders and continually learns. And it handles the new 2018 standards. For further information visit www.hla-global.com.
|
|
AJMC
Compared to the general Hispanic population, Hispanics living with HIV face higher risks of human papillomavirus–related cancers, highlighting the need for increased efforts for promoting HPV vaccination among the patient population, according to a new study. The study findings also indicate that Hispanic adults living with HIV have higher rates of cervical and penile cancer than non-Hispanic whites and non-Hispanic blacks living with the virus. Incidence rate ratios showed that among people living with HIV, Hispanic females had close to a 2-fold higher rate of cervical cancer than non-Hispanic whites but a similar rate to that of non-Hispanic blacks. There were no observed differences in vaginal and anal cancer rates, but Hispanics had lower vulvar cancer rates than non-Hispanic whites and non-Hispanic blacks.
READ MORE
American Society for Radiation Oncology via Medical Xpress
Two recent studies find advances in radiation therapy are helping to prolong or improve the lives of people with anal cancer, including those whose cancer has advanced to stage IV. Both studies were published in the flagship scientific journal of the American Society for Radiation Oncology. One study of patients with advanced-stage anal cancer whose disease has spread to the para-aortic lymph nodes found that a combination of extended-field radiation therapy and chemotherapy could substantially improve overall survival and control the cancer without increasing serious side effects. A second study found that, for patients with locally advanced anal cancer, the use of intensity modulated radiation therapy instead of conventional radiation treatment improved tolerance of radiation treatments and reduced the need for ostomy (surgery to re-route how waste exits the body).
READ MORE
Medical News Today
Obesity is a risk factor for cancer, but researchers are only now unfurling the exact mechanisms behind this connection. A new study looks at how obesity might scupper the immune system's ability to attack tumor cells. Obesity is at an all-time high in the United States.
According to the National Institutes of Health, two-thirds of adults in the U.S. are either obese or overweight.
READ MORE
Medical Xpress
A new Nature Communications study led by University of Kentucky Markey Cancer Center researchers suggests that an enzyme known as Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) is a potential therapeutic target for triple negative breast cancer. Collagen prolyl 4-hydroxylase (P4H) expression and collagen hydroxylation in cancer cells are necessary for breast cancer progression. Performed in the lab of UK College of Medicine associate professor Ren Xu, the study found that P4HA1 expression was induced in triple-negative breast cancer, and P4HA1 expression enhanced hypoxia-inducible factor (HIF) 1α stability, thereby increasing cancer stem cell population.
READ MORE
Medical Xpress
New research has shown that many Australians with rare cancers can benefit from genomic profiling. The findings of the patient-driven trial are being presented today at the Clinical Oncology Society of Australia Annual Scientific Meeting and could result in dramatic changes to the way those with rare cancers are diagnosed and treated.
The initial data from the pilot study for Nominator Trial is being presented by Professor Clare Scott from the Walter and Eliza Hall Institute of Medical Research and Peter MacCallum Cancer Centre, and was funded in part by Rare Cancers Australia.
READ MORE
Medical News Today
Scientists have uncovered a new way to curb autoimmunity and stimulate the body to fight cancer. The method uses a previously unknown druggable pathway to manipulate immune cells. The discovery concerns a molecule called tetrahydrobiopterin (BH4), which is already well-known to those who study the biology of the brain and nervous system.
READ MORE
Dark Daily
Dark Daily has covered CRISPR-Cas9 many times in previous e-briefings. Since its discovery, CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, has been at the root of astonishing breakthroughs in genetic research. It appears to fulfill precision medicine goals for patients with conditions caused by genetic mutations and has anatomic pathologists, along with the entire scientific world, abuzz with the possibilities such a tool could bring to diagnostic medicine.
All of this research has contributed to a deeper understanding of how cells function. However, as is often the case with new technologies, unforeseen and problematic questions also have arisen.
READ MORE
OncLive
Immunotherapy has garnered major traction as a treatment approach for patients with lung cancer, but there are still several unanswered questions that need to be addressed in this space, according to Roy S. Herbst, MD, PhD.
Because only a small percentage of this patient population benefits from immunotherapy, ongoing work is being geared toward acquiring a stronger understanding on the different mechanisms of resistance to this approach.
READ MORE
Hawaii News Now
A Hawaii resident, who has been living with a slow-growing yet incurable cancer since 2006, is the first person in the state to receive a new specialized radiation treatment.
The Honolulu Star-Advertiser reports the cancer in Mary Bona’s gut grew over the summer despite several rounds of chemotherapy and other treatments.
That's when her doctor found out about a treatment approved earlier this year by the U.S. Food and Drug Administration to target hard-to-reach neuroendocrine tumors.
READ MORE
| IMPORTANT DATES AND DEADLINES |
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Cancer Programs do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the authors and not of the American College of Surgeons, and the Cancer Programs.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
